首頁 > 市場調查報告書 > 製藥

藥物開發以基因為基之藥物開發

生物模擬市場規模、佔有率和成長分析（按產品、應用、治療領域、實施模式、定價模式、最終用途和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1897596

生物模擬市場規模、佔有率和成長分析（按產品、應用、治療領域、實施模式、定價模式、最終用途和地區分類）－2026-2033年產業預測

Biosimulation Market Size, Share, and Growth Analysis, By Product (Software, Services), By Application (Drug Development, Drug Discovery), By Therapeutic Area, By Deployment Model, By Pricing Model, By End Use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，生物模擬市場規模將達到 46.9 億美元，到 2025 年將達到 55 億美元，到 2033 年將達到 195.7 億美元，在預測期（2026-2033 年）內，複合年成長率為 17.2%。

由於模擬軟體的進步，生物仿真市場正在迅速擴張。這些軟體透過數學框架對現實世界系統進行建模，能夠改善系統的行為、特性和互動方式，從而帶來顯著效益，例如降低培訓和製造成本、提高產品品質和提升生產效率。這反過來又有助於減少產品召回，而產品召回是製造商最關注的問題之一。關鍵成長要素包括醫療領域軟體應用的不斷開發，以及模擬工具在汽車、電子和航太等多個行業的日益普及。此外，近期全球健康危機加速了數位科技的應用，使得模擬軟體對於最佳化業務流程和最大限度減少人際接觸至關重要，凸顯了其在解決醫療保健挑戰方面的重要性。

生物模擬市場促進因素

生物模擬市場的主要驅動力是各行業對具成本效益解決方案日益成長的需求。隨著企業尋求降低營運成本，模擬軟體的應用正在蓬勃發展。這項技術能夠實現虛擬測試和分析，使企業能夠以更有效率、更經濟的方式取代昂貴的實體原型和傳統測試方法。透過生物仿真，企業可以簡化開發流程、降低風險、加速創新並控制成本。這一趨勢表明，人們越來越認知到先進模擬工具在提高生產力和最佳化資源利用方面具有重要價值，並已在多個領域中得到應用。

壓制生物模擬市場

儘管生物模擬市場具有許多優勢，但其主要阻礙因素在於實施模擬軟體所需的高昂初始投資。這不僅包括許可費，還包括硬體升級和必要的人員培訓費用。對於預算有限的中小型企業而言，這筆財務負擔尤其沉重。因此，高昂的初始成本可能會阻礙生物模擬技術的應用，限制其在業界的廣泛普及。由此可見，財務因素仍然是許多潛在用戶進入該領域的重要障礙。

生物模擬市場趨勢

將人工智慧 (AI) 技術應用於生物模擬領域，以提高其準確性和效率，已成為該領域的一大趨勢。 AI 驅動的生物模擬工具能夠提供預測性洞察，從而實現即時性能最佳化，徹底改變醫療保健和自動駕駛汽車等產業。這種轉變不僅提升了生物模擬的價值，也使企業更有效地應對複雜多變的環境。對先進建模和模擬能力的需求持續成長，這使得 AI 成為推動生物模擬領域研發和系統效率提升的關鍵驅動力。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Simulations Plus, Inc.（USA）
Dassault Systemes（France）
Schrodinger, LLC（USA）
ACD/Labs（Canada）
Chemical Computing Group（Canada）
Physiomics PLC（UK）
Evidera（USA）
In Silico Biosciences, Inc.（USA）
INOSIM Software GmbH（Germany）
Insilico Biotechnology AG（Germany）
LeadInvent Technologies（India）
Rosa & Co. LLC（USA）
Genedata AG（Switzerland）

結論與建議

簡介目錄

Product Code: SQMIG35I2104

Biosimulation Market size was valued at USD 4.69 Billion in 2024 and is poised to grow from USD 5.5 Billion in 2025 to USD 19.57 Billion by 2033, growing at a CAGR of 17.2% during the forecast period (2026-2033).

The biosimulation market is rapidly expanding due to advancements in simulation software that models real-world systems through mathematical frameworks. These tools enhance system behaviors, properties, and interactions, delivering significant advantages such as lower training and manufacturing costs, improved product quality, and enhanced productivity. As a result, they help mitigate product recalls, a major concern for manufacturers. Key growth drivers include the rising development of software applications in medicine and the increasing implementation of simulation tools across multiple sectors like automotive, electronics, and aerospace. Additionally, the recent global health crisis has accelerated the adoption of digital technologies, making simulation software essential for optimizing processes and minimizing physical interactions in operations, highlighting its vital role in addressing healthcare challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biosimulation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biosimulation Market Segments Analysis

Global Biosimulation Market is segmented by Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use and region. Based on Product, the market is segmented into Software and Services. Based on Application, the market is segmented into Drug Development, Drug Discovery and Others. Based on Therapeutic Area, the market is segmented into Oncology, Neurology, Cardiology and Others. Based on Deployment Model, the market is segmented into On-premise and Cloud-based. Based on Pricing Model, the market is segmented into Subscription and Ownership. Based on End Use, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutes and Regulatory Authorities. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biosimulation Market

The biosimulation market is primarily propelled by the growing demand for cost-effective solutions across various industries. As organizations look to lower their operational expenses, the adoption of simulation software has surged. This technology facilitates virtual testing and analysis, allowing businesses to substitute expensive physical prototypes and traditional testing methods with more efficient and economical alternatives. By leveraging biosimulation, companies can streamline their development processes, mitigate risks, and accelerate innovation, all while keeping costs in check. This trend underscores the increasing recognition of the value that advanced simulation tools bring to enhancing productivity and optimizing resource utilization in diverse sectors.

Restraints in the Biosimulation Market

Although the biosimulation market offers numerous benefits, a major constraint lies in the substantial initial investment required for simulation software. This includes not only the costs of licensing but also expenses related to hardware upgrades and necessary staff training. Such financial burdens can be particularly challenging for small and medium-sized enterprises (SMEs), which often operate within tight budgets. As a result, these high upfront costs may deter some businesses from adopting biosimulation technologies, limiting wider accessibility and utilization within the industry. Thus, financial considerations remain a crucial barrier to entry for many potential users.

Market Trends of the Biosimulation Market

The biosimulation market is witnessing a significant trend driven by the integration of Artificial Intelligence (AI) technologies, enhancing the accuracy and efficiency of simulations. AI-powered biosimulation tools are revolutionizing industries like healthcare and autonomous vehicles by delivering predictive insights that facilitate real-time performance optimization. This shift not only elevates the value of biosimulations but also empowers organizations to navigate complex and dynamic environments more effectively. The demand for advanced modeling and simulation capabilities continues to rise, positioning AI as a key enabler in advancing research, drug development, and system efficiencies within the biosimulation landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Patent Analysis

Global Biosimulation Market Size by Product & CAGR (2026-2033)

Market Overview
Software
Services

Global Biosimulation Market Size by Application & CAGR (2026-2033)

Market Overview
Drug Development
Drug Discovery
Others

Global Biosimulation Market Size by Therapeutic Area & CAGR (2026-2033)

Market Overview
Oncology
Neurology
Cardiology
Others

Global Biosimulation Market Size by Deployment Model & CAGR (2026-2033)

Market Overview
On-premise
Cloud-based

Global Biosimulation Market Size by Pricing Model & CAGR (2026-2033)

Market Overview
Subscription
Ownership

Global Biosimulation Market Size by End Use & CAGR (2026-2033)

Market Overview
Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
Academic & Research Institutes
Regulatory Authorities

Global Biosimulation Market Size & CAGR (2026-2033)

North America (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
- US
- Canada
Europe (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Simulations Plus, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dassault Systemes (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Schrodinger, LLC (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ACD/Labs (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chemical Computing Group (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Physiomics PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evidera (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
In Silico Biosciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
INOSIM Software GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Insilico Biotechnology AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LeadInvent Technologies (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Rosa & Co. LLC (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genedata AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments